The Impact of Cirrhosis on Pancreatic Cancer Surgery: A Systematic Review and Meta-Analysis.


Journal

World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052

Informations de publication

Date de publication:
Feb 2021
Historique:
accepted: 04 10 2020
pubmed: 20 10 2020
medline: 29 5 2021
entrez: 19 10 2020
Statut: ppublish

Résumé

Cirrhosis has been considered a contraindication to major abdominal surgeries, due to increased risk for postoperative morbidity and mortality. The aim of this study was to assess the safety of pancreatectomy in cirrhotic versus non-cirrhotic patients. The present systematic review and meta-analysis was performed according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. All meta-analyses were performed using the random effects model. Eight studies were eventually included, enrolling 1229 patients (cirrhotics: 722; and Child-Pugh A: 593; Child-Pugh B/C: 129) who underwent surgery for pancreatic cancer. The overall postoperative morbidity rate was 66% (51%-80%). Infections (26%) and ascites formation/worsening (23%) were the most common postoperative complications, followed by anastomotic leak/fistula (17%). Non-cirrhotic patients were less likely to suffer from anastomotic leak/fistula (OR: 0.39; 95% CI: 0.23-0.65) and infections (OR: 0.41; 95% CI: 0.25-0.67). Postoperative mortality rate was statistically significantly lower in non-cirrhotic versus cirrhotic patients (OR: 0.18; 95% CI:0.18-0.39). The odds ratios of 1 year (OR: 0.62; 95% CI: 0.30-1.30), 2 year (OR: 0.67; 95% CI: 0.25-1.83) and 3 year all-cause mortality (OR: 0.32; 95% CI: 20.03-2.99) were not significantly different between cirrhotic versus non-cirrhotic patients. This study demonstrated that non-cirrhotic patients were less likely to undergo any type of re-intervention and had statistically significant lower postoperative mortality rates compared to patients with cirrhosis.

Sections du résumé

BACKGROUND BACKGROUND
Cirrhosis has been considered a contraindication to major abdominal surgeries, due to increased risk for postoperative morbidity and mortality. The aim of this study was to assess the safety of pancreatectomy in cirrhotic versus non-cirrhotic patients.
METHODS METHODS
The present systematic review and meta-analysis was performed according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. All meta-analyses were performed using the random effects model.
RESULTS RESULTS
Eight studies were eventually included, enrolling 1229 patients (cirrhotics: 722; and Child-Pugh A: 593; Child-Pugh B/C: 129) who underwent surgery for pancreatic cancer. The overall postoperative morbidity rate was 66% (51%-80%). Infections (26%) and ascites formation/worsening (23%) were the most common postoperative complications, followed by anastomotic leak/fistula (17%). Non-cirrhotic patients were less likely to suffer from anastomotic leak/fistula (OR: 0.39; 95% CI: 0.23-0.65) and infections (OR: 0.41; 95% CI: 0.25-0.67). Postoperative mortality rate was statistically significantly lower in non-cirrhotic versus cirrhotic patients (OR: 0.18; 95% CI:0.18-0.39). The odds ratios of 1 year (OR: 0.62; 95% CI: 0.30-1.30), 2 year (OR: 0.67; 95% CI: 0.25-1.83) and 3 year all-cause mortality (OR: 0.32; 95% CI: 20.03-2.99) were not significantly different between cirrhotic versus non-cirrhotic patients.
CONCLUSION CONCLUSIONS
This study demonstrated that non-cirrhotic patients were less likely to undergo any type of re-intervention and had statistically significant lower postoperative mortality rates compared to patients with cirrhosis.

Identifiants

pubmed: 33073316
doi: 10.1007/s00268-020-05821-7
pii: 10.1007/s00268-020-05821-7
doi:

Types de publication

Comparative Study Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

562-570

Références

Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet 383:1749–1761. https://doi.org/10.1016/S0140-6736(14)60121-5
doi: 10.1016/S0140-6736(14)60121-5 pubmed: 24480518
Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371:838–851. https://doi.org/10.1016/S0140-6736(08)60383-9
doi: 10.1016/S0140-6736(08)60383-9 pubmed: 18328931 pmcid: 2271178
Artinyan A, Marshall CL, Balentine CJ et al (2012) Clinical outcomes of oncologic gastrointestinal resections in patients with cirrhosis. Cancer 118:3494–3500. https://doi.org/10.1002/cncr.26682
doi: 10.1002/cncr.26682 pubmed: 22170573
del Olmo JA, Flor-Lorente B, Flor-Civera B et al (2003) Risk factors for nonhepatic surgery in patients with cirrhosis. World J Surg 27:647–652. https://doi.org/10.1007/s00268-003-6794-1
doi: 10.1007/s00268-003-6794-1 pubmed: 12732995
Puggioni A, Wong LL (2003) A metaanalysis of laparoscopic cholecystectomy in patients with cirrhosis. J Am CollSurg 197:921–926. https://doi.org/10.1016/j.jamcollsurg.2003.08.011
doi: 10.1016/j.jamcollsurg.2003.08.011
El-Awadi S, El-Nakeeb A, Youssef T et al (2009) Laparoscopic versus open cholecystectomy in cirrhotic patients: a prospective randomized study. Int J Surg 7:66–69. https://doi.org/10.1016/j.ijsu.2008.10.013
doi: 10.1016/j.ijsu.2008.10.013 pubmed: 19028148
Schiff J, Misra M, Rendon G et al (2005) Laparoscopic cholecystectomy in cirrhotic patients. SurgEndosc 19:1278–1281. https://doi.org/10.1007/s00464-004-8823-z
doi: 10.1007/s00464-004-8823-z
Mansour A, Watson W, Shayani V, Pickleman J (1997) Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 122:730–736. https://doi.org/10.1016/s0039-6060(97)90080-5
doi: 10.1016/s0039-6060(97)90080-5 pubmed: 9347849
Neeff HP, Streule GC, Drognitz O et al (2014) Early mortality and long-term survival after abdominal surgery in patients with liver cirrhosis. Surgery 155:623–632. https://doi.org/10.1016/j.surg.2013.11.009
doi: 10.1016/j.surg.2013.11.009 pubmed: 24468037
Farnsworth N, Fagan SP, Berger DH, Awad SS (2004) Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 188:580–583. https://doi.org/10.1016/j.amjsurg.2004.07.034
doi: 10.1016/j.amjsurg.2004.07.034 pubmed: 15546574
Sorensen HT, Friis S, Olsen JH et al (1998) Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28:921–925. https://doi.org/10.1002/hep.510280404
doi: 10.1002/hep.510280404 pubmed: 9755226
Goldacre MJ, Wotton CJ, Yeates D et al (2008) Liver cirrhosis, other liver diseases, pancreatitis and subsequent cancer: record linkage study. Eur J GastroenterolHepatol 20:384–392. https://doi.org/10.1097/MEG.0b013e3282f4489f
doi: 10.1097/MEG.0b013e3282f4489f
Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Bjornsson E (2011) Increased risk for malignant neoplasms among patients with cirrhosis. ClinGastroenterolHepatol 9:168–174. https://doi.org/10.1016/j.cgh.2010.10.014
doi: 10.1016/j.cgh.2010.10.014
Bottger TC, Junginger T (1999) Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. World J Surg 23:162–164. https://doi.org/10.1007/pl00013170
doi: 10.1007/pl00013170
Winter JM, Cameron JL, Campbell KA et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J GastrointestSurg 10:1191–1199. https://doi.org/10.1016/j.gassur.2006.08.018
doi: 10.1016/j.gassur.2006.08.018
DeOliveira ML, Winter JM, Schafer M et al (2006) Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 244:931–939. https://doi.org/10.1097/01.sla.0000246856.03918.9a
doi: 10.1097/01.sla.0000246856.03918.9a pubmed: 17122618 pmcid: 1856636
Grobmyer SR, Pieracci FM, Allen PJ et al (2007) Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am CollSurg 204:356–364. https://doi.org/10.1016/j.jamcollsurg.2006.11.017
doi: 10.1016/j.jamcollsurg.2006.11.017
El Nakeeb A, Sultan AM, Salah T et al (2013) Impact of cirrhosis on surgical outcome after pancreaticoduodenectomy. World J Gastroenterol 19:7129–7137. https://doi.org/10.3748/wjg.v19.i41.7129
doi: 10.3748/wjg.v19.i41.7129 pubmed: 24222957 pmcid: 3819549
Fuks D, Sabbagh C, Yzet T et al (2012) Cirrhosis should not be considered as an absolute contraindication for pancreatoduodenectomy. Hepatogastroenterology 59:881–883. https://doi.org/10.5754/hge10509
doi: 10.5754/hge10509 pubmed: 22469737
Futagawa Y, Yanaga K, Kosuge T et al (2019) Outcomes of pancreaticoduodenectomy in patients with chronic hepatic dysfunction including liver cirrhosis: results of a retrospective multicenter study by the Japanese society of hepato-biliary-pancreatic surgery. J HepatobiliaryPancreatSci 26:310–324. https://doi.org/10.1002/jhbp.630
doi: 10.1002/jhbp.630
Sethi H, Srinivasan P, Marangoni G et al (2008) Pancreaticoduodenectomy with radical lymphadenectomy is not contraindicated for patients with established chronic liver disease and portal hypertension. HepatobiliaryPancreat Dis Int 7:82–85
Butler JR, Kays JK, House MG et al (2019) Outcomes of pancreatoduodenectomy in the cirrhotic patient: risk stratification and meta-analysis. HPB 21:301–309. https://doi.org/10.1016/j.hpb.2018.08.002
doi: 10.1016/j.hpb.2018.08.002 pubmed: 30269948
Regimbeau J-M, Rebibo L, Dokmak S et al (2015) The short- and long-term outcomes of pancreaticoduodenectomy for cancer in child A patients are acceptable: a patient-control study from the Surgical French Association report for pancreatic surgery. J SurgOncol 111:776–783. https://doi.org/10.1002/jso.23856
doi: 10.1002/jso.23856
Warnick P, Mai I, Klein F et al (2011) Safety of pancreatic surgery in patients with simultaneous liver cirrhosis: a single center experience. Pancreatology 11:24–29. https://doi.org/10.1159/000323961
doi: 10.1159/000323961 pubmed: 21336005
Sterne JA, Hernan MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https://doi.org/10.1136/bmj.i4919
doi: 10.1136/bmj.i4919 pubmed: 27733354 pmcid: 5062054
Setiawan VW, Stram DO, Porcel J et al (2016) Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology 64:1969–1977. https://doi.org/10.1002/hep.28677
doi: 10.1002/hep.28677 pubmed: 27301913 pmcid: 5115980
Kabbany MN, ConjeevaramSelvakumar PK, Watt K et al (2017) Prevalence of nonalcoholicsteatohepatitis-associated cirrhosis in the United States: an analysis of national health and nutrition examination survey data. Am J Gastroenterol 112:581–587. https://doi.org/10.1038/ajg.2017.5
doi: 10.1038/ajg.2017.5 pubmed: 28195177
Becker AE, Hernandez YG, Frucht H, Lucas AL (2014) Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol 20:11182–11198. https://doi.org/10.3748/wjg.v20.i32.11182
doi: 10.3748/wjg.v20.i32.11182 pubmed: 25170203 pmcid: 4145757
Tramacere I, Scotti L, Jenab M et al (2010) Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J cancer 126:1474–1486. https://doi.org/10.1002/ijc.24936
doi: 10.1002/ijc.24936 pubmed: 19816941
Yeo TP, Lowenfels AB (2012) Demographics and epidemiology of pancreatic cancer. Cancer J 18:477–484. https://doi.org/10.1097/PPO.0b013e3182756803
doi: 10.1097/PPO.0b013e3182756803 pubmed: 23187833
Genkinger JM, Spiegelman D, Anderson KE et al (2009) Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer EpidemiolBiomarkPrev 18:765–776. https://doi.org/10.1158/1055-9965.EPI-08-0880
doi: 10.1158/1055-9965.EPI-08-0880
Larsson SC, Orsini N, Wolk A (2007) Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J cancer 120:1993–1998. https://doi.org/10.1002/ijc.22535
doi: 10.1002/ijc.22535 pubmed: 17266034
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638. https://doi.org/10.1056/NEJMoa021423
doi: 10.1056/NEJMoa021423 pubmed: 12711737
Stocks T, Rapp K, Bjorge T et al (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6:e1000201. https://doi.org/10.1371/journal.pmed.1000201
doi: 10.1371/journal.pmed.1000201 pubmed: 20027213 pmcid: 2791167
Bhangui P, Laurent A, Amathieu R, Azoulay D (2012) Assessment of risk for non-hepatic surgery in cirrhotic patients. J Hepatol 57:874–884. https://doi.org/10.1016/j.jhep.2012.03.037
doi: 10.1016/j.jhep.2012.03.037 pubmed: 22634123
Suman A, Barnes DS, Zein NN et al (2004) Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. ClinGastroenterolHepatol 2:719–723. https://doi.org/10.1016/s1542-3565(04)00296-4
doi: 10.1016/s1542-3565(04)00296-4
Hoteit M-A, Ghazale A-H, Bain A-J et al (2008) Model for end-stage liver disease score versus child score in predicting the outcome of surgical procedures in patients with cirrhosis. World J Gastroenterol 14:1774–1780. https://doi.org/10.3748/wjg.14.1774
doi: 10.3748/wjg.14.1774 pubmed: 18350609 pmcid: 2695918
Kadry Z, Schaefer EW, Shah RA et al (2016) Portal hypertension: an underestimated entity? Ann Surg 263:986–991. https://doi.org/10.1097/SLA.0000000000001299
doi: 10.1097/SLA.0000000000001299 pubmed: 26181478
Befeler AS, Palmer DE, Hoffman M et al (2005) The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch Surg 140:650–654. https://doi.org/10.1001/archsurg.140.7.650
doi: 10.1001/archsurg.140.7.650 pubmed: 16027329
Busquets J, Peláez N, Gil M et al (2016) Is pancreaticoduodenectomy a safe procedure in the cirrhotic patient? CIR ESP 94:385–391. https://doi.org/10.1016/j.ciresp.2016.01.002 .

Auteurs

Dimitrios Schizas (D)

First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece. schizasad@gmail.com.

Spyridon Peppas (S)

Department of Gastroenterology, Athens Naval Hospital, Athens, Greece.

Stefanos Giannopoulos (S)

Department of Surgery, 251 VA and Hellenic Air Force Hospital, Athens, Greece.

Vasiliki Lagopoulou (V)

Department of Surgery, 251 VA and Hellenic Air Force Hospital, Athens, Greece.

Konstantinos S Mylonas (KS)

First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Spyridon Giannopoulos (S)

First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Dimitrios Moris (D)

Department of Surgery, Duke University Medical Center, Durham, NC, USA.

Evangelos Felekouras (E)

First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Konstantinos Toutouzas (K)

First Propedeutic Department of Surgery, Hippocration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH